Market Cap 5.23B
Revenue (ttm) 47.07M
Net Income (ttm) -223.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475.59%
Debt to Equity Ratio 0.00
Volume 648,300
Avg Vol 1,020,306
Day's Range N/A - N/A
Shares Out 71.95M
Stochastic %K 84%
Beta 2.21
Analysts Strong Sell
Price Target $116.71

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 5300
Address:
500 North Beacon Street, 4th Floor, Watertown, United States
SuperGreenToday
SuperGreenToday Feb. 2 at 1:14 PM
$KYMR Share Price: $72.73 Contract Selected: Aug 21, 2026 $95 Calls Buy Zone: $4.74 – $5.86 Target Zone: $8.78 – $10.73 Potential Upside: 75% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
cheruskian
cheruskian Feb. 1 at 9:29 AM
$KYMR the way the market is trading biotech these days we are probably going to see the 60s again here.
0 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 4:01 PM
$KYMR surges 68.9% in 6 months — what's driving the rally? The phase IIb BREADTH study for KT-621 in eosinophilic asthma marks a key step forward for developing oral treatments for type II inflammatory diseases, with top-line data expected in late 2027. Plus, KYMR holds a Zacks Rank #2 (Buy), signaling strong potential. See what makes the investment case strong for Kymera here 👉 https://www.zacks.com/stock/news/2826252/kymr-initiates-dosing-in-mid-stage-asthma-study-of-lead-candidate?cid=sm-stocktwits-2-2826252-body-31192&ADID=SYND_STOCKTWITS_TWEET_2_2826252_BODY_31192
0 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 2:18 PM
$KYMR just hit a key clinical milestone — this is one to watch Kymera Therapeutics has initiated phase IIb dosing of its oral lead candidate KT-621 in eosinophilic asthma, targeting STAT6, with top-line BREADTH study data expected in late 2027. Progress like this keeps the pipeline narrative alive. See the full study details here 👉 https://www.zacks.com/stock/news/2826252/kymr-initiates-dosing-in-mid-stage-asthma-study-of-lead-candidate?cid=sm-stocktwits-2-2826252-teaser-31162&ADID=SYND_STOCKTWITS_TWEET_2_2826252_TEASER_31162
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 30 at 12:50 PM
$KYMR Share Price: $73.91 Contract Selected: Aug 21, 2026 $95 Calls Buy Zone: $4.74 – $5.86 Target Zone: $8.79 – $10.75 Potential Upside: 75% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MikeyNJ
MikeyNJ Jan. 28 at 3:08 PM
$KYMR Barclay's raises price target from $119 to $133. Amazing!
0 · Reply
MooseG
MooseG Jan. 27 at 12:33 PM
$KYMR this looks dead for awhile.
1 · Reply
JFais
JFais Jan. 23 at 8:39 PM
Better stated: $APGE- we've seen a good number of + biotech binaries lately, perhaps due for a significant (downward) revaluation here? 4x avg volume so far on the high side, but certainly far from panic levels (as of yet) Also, atopic dermatitis very crowded & while the pie is very large, it's limited as well (yes, it can be both) New drugs shining like $CRVS ITK will be at the expense of other potential entrants like $APGE or $KYMR IMO
0 · Reply
JFais
JFais Jan. 21 at 2:14 PM
$CRVS- updated EV gap vs $KYMR $APGE $NKTR
2 · Reply
cheruskian
cheruskian Jan. 21 at 7:23 AM
I'm genuinely curious about the reason behind those $KYMR buyout speculations. They have enough cash in the bank to get at least two wholly owned assets through phase 3 trials without limiting their research operations. They could become the next$REGN Why would they sell out now, or anytime soon?
1 · Reply
Latest News on KYMR
Kymera Therapeutics Announces Proposed Public Offering

Dec 8, 2025, 4:01 PM EST - 2 months ago

Kymera Therapeutics Announces Proposed Public Offering


This Drugmaker's Stock Is Soaring Over 40% Monday

Dec 8, 2025, 3:50 PM EST - 2 months ago

This Drugmaker's Stock Is Soaring Over 40% Monday


Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum

Dec 8, 2025, 9:15 AM EST - 2 months ago

Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum


The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 6 months ago

The Best Small-Cap Stocks to Buy Now

DNLI WAY


Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Jun 25, 2025, 7:05 AM EDT - 8 months ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update


Kymera: Protein Degradation Could Drive Dupixent-Like Value

Dec 7, 2024, 1:07 AM EST - 1 year ago

Kymera: Protein Degradation Could Drive Dupixent-Like Value


SuperGreenToday
SuperGreenToday Feb. 2 at 1:14 PM
$KYMR Share Price: $72.73 Contract Selected: Aug 21, 2026 $95 Calls Buy Zone: $4.74 – $5.86 Target Zone: $8.78 – $10.73 Potential Upside: 75% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
cheruskian
cheruskian Feb. 1 at 9:29 AM
$KYMR the way the market is trading biotech these days we are probably going to see the 60s again here.
0 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 4:01 PM
$KYMR surges 68.9% in 6 months — what's driving the rally? The phase IIb BREADTH study for KT-621 in eosinophilic asthma marks a key step forward for developing oral treatments for type II inflammatory diseases, with top-line data expected in late 2027. Plus, KYMR holds a Zacks Rank #2 (Buy), signaling strong potential. See what makes the investment case strong for Kymera here 👉 https://www.zacks.com/stock/news/2826252/kymr-initiates-dosing-in-mid-stage-asthma-study-of-lead-candidate?cid=sm-stocktwits-2-2826252-body-31192&ADID=SYND_STOCKTWITS_TWEET_2_2826252_BODY_31192
0 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 2:18 PM
$KYMR just hit a key clinical milestone — this is one to watch Kymera Therapeutics has initiated phase IIb dosing of its oral lead candidate KT-621 in eosinophilic asthma, targeting STAT6, with top-line BREADTH study data expected in late 2027. Progress like this keeps the pipeline narrative alive. See the full study details here 👉 https://www.zacks.com/stock/news/2826252/kymr-initiates-dosing-in-mid-stage-asthma-study-of-lead-candidate?cid=sm-stocktwits-2-2826252-teaser-31162&ADID=SYND_STOCKTWITS_TWEET_2_2826252_TEASER_31162
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 30 at 12:50 PM
$KYMR Share Price: $73.91 Contract Selected: Aug 21, 2026 $95 Calls Buy Zone: $4.74 – $5.86 Target Zone: $8.79 – $10.75 Potential Upside: 75% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MikeyNJ
MikeyNJ Jan. 28 at 3:08 PM
$KYMR Barclay's raises price target from $119 to $133. Amazing!
0 · Reply
MooseG
MooseG Jan. 27 at 12:33 PM
$KYMR this looks dead for awhile.
1 · Reply
JFais
JFais Jan. 23 at 8:39 PM
Better stated: $APGE- we've seen a good number of + biotech binaries lately, perhaps due for a significant (downward) revaluation here? 4x avg volume so far on the high side, but certainly far from panic levels (as of yet) Also, atopic dermatitis very crowded & while the pie is very large, it's limited as well (yes, it can be both) New drugs shining like $CRVS ITK will be at the expense of other potential entrants like $APGE or $KYMR IMO
0 · Reply
JFais
JFais Jan. 21 at 2:14 PM
$CRVS- updated EV gap vs $KYMR $APGE $NKTR
2 · Reply
cheruskian
cheruskian Jan. 21 at 7:23 AM
I'm genuinely curious about the reason behind those $KYMR buyout speculations. They have enough cash in the bank to get at least two wholly owned assets through phase 3 trials without limiting their research operations. They could become the next$REGN Why would they sell out now, or anytime soon?
1 · Reply
JuggernautRaider
JuggernautRaider Jan. 18 at 9:18 PM
$ALT where was it discovered that the lean mass preserving weight loss in pemvi’s trials wasn’t caused by it? Even the placebo arm didn’t show it, although it outperformed all historical norms. @BioRich here are three biotech gems. Check them out - it’s more fun to be positive on stocks than a Negative Nancy. LMK what you think about $TLSA $KYMR and $IXHL are all very intriguing to me (KYMR to hold for a buyout, TLSA & IXHL to hold long like CCCC or IMRX). Thoughts on these other ones? We can formally agree to disagree on AltImmune. I am a bull 🐂 and you are a 🐻 we all get it 🚀
2 · Reply
JFais
JFais Jan. 17 at 1:48 PM
Per your request: EV gap for $CRVS vs $KYMR $APGE $NKTR All in atopic dermatitis space, though obviously far from being apples to apples (more like apples to fruit loops). Still fun re point of comparison
1 · Reply
MooseG
MooseG Jan. 16 at 8:26 PM
$KYMR at close to pre-trial data news levels. Didnt see that coming.
2 · Reply
ZacksResearch
ZacksResearch Jan. 5 at 8:20 PM
$KYMR surged 82.4% over the past year — what's driving this biotech rocket? 🚀 ✅ Positive phase Ib BroADen study results for KT-621 in eczema ✅ FDA's Fast Track designation boosts prospects 🚀 Outperforming industry, sector & S&P 500 See why current investors might want to hold on here 👉 https://www.zacks.com/stock/news/2812002/kymr-skyrockets-824-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2812002-body-27426&ADID=SYND_STOCKTWITS_TWEET_2_2812002_BODY_27426
0 · Reply
ZacksResearch
ZacksResearch Jan. 5 at 7:20 PM
$KYMR up 82.4% in a year — and biotech bulls are eyeing what comes next 👀 The rally follows strong phase Ib BroADen data for KT-621 and FDA Fast Track designation for atopic dermatitis, a combo that put Kymera firmly on investors’ radar. Is there more upside potential into 2026? Full breakdown here 👉 https://www.zacks.com/stock/news/2812002/kymr-skyrockets-824-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2812002-teaser-27425&ADID=SYND_STOCKTWITS_TWEET_2_2812002_TEASER_27425
0 · Reply
MikeyNJ
MikeyNJ Jan. 5 at 6:38 PM
$KYMR filled most of that big gap up. 23 analysts cover KYMR with average 12 month target of $117. Looks like a pretty good entry point.
1 · Reply
frenulum1
frenulum1 Jan. 2 at 8:40 PM
$KYMR sell the news.. textbook biotech play
0 · Reply
Arcides
Arcides Jan. 2 at 7:09 PM
$KYMR gaps near former all time high levels usually find sellers...not good anymore, very close to fill the gap
0 · Reply
MikeyNJ
MikeyNJ Jan. 2 at 5:39 PM
$KYMR This is typical trading for KYMR. It's still pre-revenue and therefore volatile. Go back over the past few years and look at the chart. In 2023 it rallied from $12 to $43. It then retraced to $29 only to rally back to $50 in 2024. From September 2024 it sold off from $50 back to $22 by March 2025. From there it rallied to the recent high of $103 on the very promising data. The company was also able to take advantage of its stock strength raising $700M in cash at $84/share bringing its cash to approx. $1.6B. Going forward they have adequate cash to advance the pipeline with no need for further dilution. Every analyst has raised price targets since the data with an average target of $117. The volatility is nothing new for KYMR and presents an excellent opportunity to enter. It will hit those analyst targets over time and they will be raised again. Happy New Year!
0 · Reply
frenulum1
frenulum1 Jan. 2 at 3:53 PM
$KYMR CEO wishes all shareholders a Happy New Year.. while unloading a sizable stake
2 · Reply
deedeethegenius
deedeethegenius Dec. 30 at 9:20 PM
0 · Reply
CharacterCharm
CharacterCharm Dec. 27 at 3:33 PM
$KYMR Confidence will depend on whether guidance becomes dependable; customer retention trends will be critical to monitor — discipline in guidance could rebuild trust. The thesis tightens only when delivery matches ambition.
0 · Reply